Natural product-based therapy for pulmonary arterial hypertension: p53 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 3/June/2015, 10.11 am

Molecular therapy for Human Cancer: Palmitate suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via up regulation of its target gene, 2/June/2014, 7.23 am
June 3, 2015
Lifespan extension therapy: IL-6 increases life span via up regulation of its target gene BubR1, 3/June/2015, 10.14 pm
June 3, 2015
Show all

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054] by Prof. Thistlethwaite PA, Li X and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for pulmonary arterial hypertension: p53 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3 

Significance:  p53, by increasing the expression of their target gene, it may decrease the expression of Notch3. Thus, pharmacological formulations encompassing “p53 or its activators” may be used to treat pulmonary arterial hypertension.

Undisclosed information: How p53  decreases the expression of Notch3 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Natural product-based therapy for pulmonary arterial hypertension: p53 inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 3/June/2015, 10.11 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.